Pulse Biosciences (NASDAQ:PLSE) COO Liane Rae Teplitsky Purchases 1,034 Shares

Pulse Biosciences, Inc (NASDAQ:PLSE) COO Liane Rae Teplitsky acquired 1,034 shares of the stock in a transaction on Friday, August 28th. The shares were bought at an average cost of $48.35 per share, for a total transaction of $49,993.90. Following the purchase, the chief operating officer directly owned 2,070 shares of the company’s stock, valued at $100,084.50. The trade was a 99.81% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

Liane Rae Teplitsky also recently made the following trade(s):

• On Wednesday, August 26th, Liane Rae Teplitsky bought 1,036 shares of Pulse Biosciences stock. The stock was bought at an average cost of $48.23 per share, with a total value of $49,966.28.

Pulse Biosciences Stock Down 2.0%

Shares of PLSE traded down $0.99 during midday trading on Friday, reaching $47.57. The company had a trading volume of 262,703 shares, compared to its average volume of 406,808. Pulse Biosciences, Inc has a 1-year low of $12.56 and a 1-year high of $50.90. The firm has a 50 day simple moving average of $35.38 and a 200-day simple moving average of $27.00. The stock has a market cap of $3.29 billion, a PE ratio of -40.31 and a beta of 1.61.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.07). Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. The firm had revenue of $0.43 million for the quarter, compared to analyst estimates of $0.53 million. As a group, sell-side analysts anticipate that Pulse Biosciences, Inc will post -1.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC acquired a new stake in shares of Pulse Biosciences during the first quarter valued at about $323,000. Creative Planning increased its holdings in Pulse Biosciences by 26.3% in the 2nd quarter. Creative Planning now owns 18,971 shares of the company’s stock valued at $286,000 after purchasing an additional 3,951 shares during the last quarter. Legal & General Group Plc increased its holdings in Pulse Biosciences by 57.7% in the 2nd quarter. Legal & General Group Plc now owns 22,415 shares of the company’s stock valued at $338,000 after purchasing an additional 8,197 shares during the last quarter. Norges Bank purchased a new stake in Pulse Biosciences in the second quarter valued at approximately $302,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in Pulse Biosciences in the second quarter valued at approximately $158,000. Hedge funds and other institutional investors own 76.95% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Oppenheimer reaffirmed an “outperform” rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Wall Street Zen cut Pulse Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Mizuho set a $45.00 price objective on Pulse Biosciences in a research report on Monday, August 10th. Finally, Needham & Company LLC assumed coverage on Pulse Biosciences in a research note on Monday, August 17th. They set a “buy” rating and a $58.00 target price for the company. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $45.25.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.